This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Omnicell Introduces Groundbreaking Mandarin-Language Medication Automation System For Use In Chinese Clinical Settings

Stocks in this article: OMCL

MOUNTAIN VIEW, Calif., Nov. 28, 2011 /PRNewswire/ -- Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication and supply management solutions and analytics software for healthcare facilities, today announced it has launched Mandarin-language versions of its G4 medication automation products for clinical use in China. The successful language conversion of Omnicell medication cabinets enables Chinese hospitals to access advances in operational improvements similar to those made available in English-speaking markets earlier this year when Omnicell launched its new automation platform.

This groundbreaking medication automation system was first implemented at Peking Union Medical College Hospital (PUMCH) in Beijing. A recently completed multi-month pilot study of the Mandarin-language Omnicell automated dispensing cabinets (ADCs) at PUMCH found that the Omnicell ADCs save each floor nurse nearly two hours per day that were previously spent locating medications and which can now be re-directed back to patient care. The hospital has plans to extend its use of Omnicell ADCs to other areas of the hospital.

"By automating the medication dispensing and administration process, we are able to store and retrieve medications securely from the Omnicell ADCs on the patient floors, which are restocked automatically by the pharmacy staff," said Weinan Liu, chief nurse, Peking Union Medical College Hospital. "The Omnicell automation process significantly reduces the time our nursing staff spends manually retrieving medications from the central pharmacy. This allows our nurses to focus more time on patient care."

In a news segment titled " Return Time to Nurses, Return Nurses to Patients," a China national television network recently featured the Omnicell medication automation advancements at PUMCH as a leading example of improvements being made in the Chinese healthcare system.

PUMCH is a renowned 1,800-bed general hospital affiliated with both Peking Union Medical College and the Chinese Academy of Medical Sciences. It has been a top-ranked hospital in China for over 80 years and has been recognized by Central Government agencies and local government agencies for its outstanding medical service and quality patient care with over 19 awards such as, "Top Ten Hospitals in Beijing" and "Top 100 National Hospitals."

"The development of a Mandarin-language automation system user interface is the culmination of a significant Omnicell investment and demonstrates our unmatched commitment to bringing advanced medication automation solutions to the Chinese market," said Randall Lipps, Omnicell president, chairman and CEO. "We believe we are the first major supplier of automation to install Mandarin language ADCs in this market."

Following the successful conversion of Omnicell's breakthrough G4 medication automation platform for the special language requirements of China, the company has announced a partnership with China Resources Beijing Pharmaceutical Co. Ltd., a subsidiary of China Resources Pharmaceutical Group, to distribute Omnicell automated medication dispensing systems in China.

Early in 2011, the Chinese Ministry of Commerce released a five-year plan that commits the Chinese pharmaceutical distribution industry to consolidate into three primary pharmaceutical suppliers, one of which is China Resources Pharmaceutical. The plan further encourages pharmaceutical distribution companies to modernize the distribution process and improve the supply chain and control of medication.

1 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,827.75 +12.81 0.07%
S&P 500 2,072.83 +5.80 0.28%
NASDAQ 4,787.3170 +29.0650 0.61%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs